MedTrace Logo

Study of Multiple Ascending Dose of KBL693 in Healthy Participants

NCT04307173 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2021-02-21

No results posted yet for this study

Summary

The study is designed to investigate the safety and tolerability of KBL693 in healthy volunteers. KBL693 has been developed as a potential new treatment for moderate to severe asthma..

Conditions

  • Moderate to Severe Asthma

Interventions

DRUG

KBL693

Part 1: 680 mg/day of KBL693 or Placebo; Route of Administration: Oral

DRUG

KBL693

Part 2: 6800 mg/day of KBL693 or Placebo; Route of Administration: Oral

Sponsors & Collaborators

  • Novotech (Australia) Pty Limited

    collaborator INDUSTRY

  • KoBioLabs

    lead INDUSTRY

Principal Investigators

  • Lara Hatchuel, Dr · Linear Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-14
Primary Completion
2020-10-30
Completion
2020-11-12

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04307173 on ClinicalTrials.gov